Volunteers Sought for Testing HIV Vaccine: UM Institute to Take Part in Research on GeoVax Product
Posted on: Saturday, 15 April 2006, 06:00 CDT
By Dennis O'Brien, The Baltimore Sun
Apr. 15--The University of Maryland's Institute of Human Virology is one of four research centers nationwide seeking volunteers to test an experimental HIV vaccine.
"We're accepting volunteers immediately," said Dr. William A. Blattner, director of the institute's Epidemiology and Prevention Division.
The vaccine was developed at Emory University in Atlanta, and is being marketed by GeoVax Inc., an Atlanta biotech company. Clinical trials also are being conducted at St. Louis University, Vanderbilt University and the University of Alabama at Birmingham.
The vaccine is designed to prevent HIV infection, will be given to volunteers who are HIV negative in a series of four doses over two months. The first two doses contain fragments of DNA from the virus, which will trigger the immune system. The second two doses contain an altered pox virus designed to boost the immune system, Blattner said.
Blattner said he anticipates delivery of the first vaccine doses in the next week to 10 days. "Once it's here, we'll be ready to start vaccinating," he said.
If approved for market, the vaccine will target sexually active adults 18 to 45 years old. "One of the important things to remember is 10 people getting infected around the world every minute every day. There's a huge need for this vaccine," Blattner said.
The vaccine was developed at Emory's Yerkes National Primate Research Center, where work began in 1997. In tests on monkeys, it protected 22 of 23 rhesus macaques for more than three years, said Holly Korschun, an Emory spokeswoman.
The product is one of more than 30 preventive AIDS vaccines in the early stages of human clinical trials in two dozen countries, according to the International AIDS Vaccine Initiative, a prevention group.
A prototype vaccine was tested in 2003 and 2004 at other research centers. The testing at Maryland and the other three centers is an step in the FDA approval process, Korschun said.
"It's one of the most promising HIV vaccines being put out there for testing," Blattner said.
Four volunteers are being sought, he said. If initial tests show the vaccine is safe, additional tests involving more volunteers will be conducted.
By next year, Blattner said, the institute will need up to 100 volunteers for HIV vaccine testing.
-----
Copyright (c) 2006, The Baltimore Sun
Distributed by Knight Ridder/Tribune Business News.
For information on republishing this content, contact us at (800) 661-2511 (U.S.), (213) 237-4914 (worldwide), fax (213) 237-6515, or e-mail reprints@krtinfo.com.
Source: The Baltimore Sun, Maryland
Related Articles
- Emory Conference Center Hotel to Become the First LEED Certified Conference Center in Atlanta
- Viral Genetics, Inc. Unveils Potential Mechanism of Action in HIV/AIDS Research, Accepted to Present Findings at Prestigious IHV Meeting
- University of Michigan Hospitals and Health Centers Completes System-Wide Conversion to Masimo SET Pulse Oximetry Technology
- Nokia Siemens Networks Enters Into Significant Partnership With IBM That Includes Transfer of Research and Development Center Activities in Munich and Berlin, Germany
- Sinovac Commences Vaccination on Volunteers for Phase II Clinical Trial on Pandemic Influenza H5N1 Vaccine
- Sinovac Commences Vaccination of Volunteers for the Clinical Research of Pandemic Influenza Vaccine (H5N1)
- Robert Wood Johnson University Hospital Recognized As an ABIOMED Center of Excellence; Selection Based on Dedication to Patient Outcomes and Recovery Rates for Patients in Acute Heart Failure
- Construction of New University of Illinois Research Park Under Way
- Wyse Technology Establishes Asia Pacific Headquarters and Research and Development Center in Beijing
- University of Maryland Researchers Develop Anthrax Tracking Method
 |
 |
User Comments (0)
RSS Feeds